A New Strategy for Discontinuation of Dual Antiplatelet Therapy: The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)

The goal of this study was to evaluate shorter duration (3 months) dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation. There have been few published reports of prospective randomized clinical studies comparing the safety and efficacy of shorter duration DAPT after DES impla...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2012-10, Vol.60 (15), p.1340-1348
Main Authors: KIM, Byeong-Keuk, HONG, Myeong-Ki, LEE, Seung-Hwan, YOON, Jung-Han, HONG, Bum-Kee, KWON, Hyuck-Moon, JANG, Yangsoo, SHIN, Dong-Ho, NAM, Chung-Mo, KIM, Jung-Sun, KO, Young-Guk, CHOI, Donghoon, KANG, Tae-Soo, PARK, Byoung-Eun, KANG, Woong-Chol
Format: Article
Language:English
Subjects:
Angioplasty, Balloon, Coronary
Biological and medical sciences
Cardiology. Vascular system
Coronary Angiography
Coronary Stenosis - diagnostic imaging
Coronary Stenosis - drug therapy
Coronary Stenosis - surgery
Drug-Eluting Stents
Female
Follow-Up Studies
Humans
Male
Medical sciences
Middle Aged
Platelet Aggregation Inhibitors - therapeutic use
Practice Guidelines as Topic
Prospective Studies
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Sirolimus - analogs & derivatives
Sirolimus - pharmacology
Time Factors
Treatment Outcome
Withholding Treatment - standards
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The goal of this study was to evaluate shorter duration (3 months) dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation. There have been few published reports of prospective randomized clinical studies comparing the safety and efficacy of shorter duration DAPT after DES implantation. We randomly assigned 2,117 patients with coronary artery stenosis into 2 groups according to DAPT duration and stent type: 3-month DAPT following Endeavor zotarolimus-eluting stent (E-ZES) implantation (E-ZES+3-month DAPT, n=1,059) versus 12-month DAPT following the other DES implantation (standard therapy, n=1,058). We hypothesized that the E-ZES+3-month DAPT would be noninferior to the standard therapy for the primary composite endpoint (cardiovascular death, myocardial infarction, stent thrombosis, target\vessel revascularization, or bleeding) at 1 year. The primary endpoint occurred in 40 (4.7%) patients assigned to E-ZES+3-month DAPT compared with 41 (4.7%) patients assigned to the standard therapy (difference: 0.0%; 95% confidence interval [CI]: -2.5 to 2.5; p=0.84; p
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2012.06.043